Alexion Pharm Inc (ALXN) 130.36 $ALXN SmarTrend
Post# of 273254
Posted On: 09/22/2016 7:05:18 AM
Alexion Pharm Inc (ALXN) 130.36 $ALXN
SmarTrend Watching for Potential Rebound in Shares of Alexion Pharmaceuticals After 2.29% Loss
Comtex SmarTrend(R) - Wed Sep 21, 1:49PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $128.10 to a high of $132.83. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $128.42 on volume of 419,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 130.36 (-1.37)
Watch for Alexion Pharmaceuticals to Potentially Pullback After Gaining 1.79% Yesterday
Comtex SmarTrend(R) - Wed Sep 14, 1:36PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $126.59 to a high of $130.39. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $129.52 on volume of 397,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 130.36 (-1.37)
Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare Diseases
BusinessWire - Tue Sep 13, 3:05PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of Uncommon Strength, a global campaign to raise awareness of rare diseases through the celebration of the extraordinary resilience and inner strength of those impacted by these diseases. Uncommon Strength (www.UncommonStrength.com) supports global rare disease communities, including those impacted by atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D) with educational information as well as interactive social media elements to unite the community.
ALXN: 130.36 (-1.37)
Don’t Get Caught with These Stocks this Week According to Forcerank
ESTMZ - Tue Sep 13, 8:16AM CDT
Each week Forcerank runs a variety of games covering different industries. What we have found, is that the lowest ranked companies in their respective games deliver the biggest negative price movement for that week. This week the losers include...
SKYW: 25.69 (+0.33), SPY: 215.82 (+2.40), BX: 26.35 (+0.39), SHAK: 34.35 (+0.25), TRMB: 27.40 (+0.54), AMCX: 51.42 (+0.47), ALXN: 130.36 (-1.37), VFC: 56.72 (+0.58), CTRP: 45.33 (+1.24), INTU: 110.78 (+1.81), YNDX: 21.54 (+0.84)
Everbridge to Showcase Safety Connection(TM) and Growing Partner Ecosystem at ASIS 2016
BusinessWire - Thu Sep 08, 4:26PM CDT
Everbridge, a global software company that provides critical communications and enterprise safety applications to help keep people safe and businesses running, will have a significant presence at global security technology conference, ASIS 2016 (September 12 - 15 in Orlando, Florida). The company will be in booth #1773 to highlight the latest enhancements to Safety Connection(TM), designed to help businesses quickly assess threats, locate people potentially in harm's way and automate actions and communicate with their employees when critical events occur. Everbridge will also participate in a joint speaking session with customer, Alexion Pharmaceuticals Inc., and demonstrate a variety of technical integrations and partnerships with other leading security providers throughout the show.
ALXN: 130.36 (-1.37)
Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Arpita Dutt - Zacks Investment Research - Wed Sep 07, 8:30AM CDT
Although it was a relatively slow week for the biotech sector, companies like CoLucid (CLCD) and Dynavax were in the news with pipeline updates.
DVAX: 11.67 (-0.33), BIIB: 312.00 (+4.95), CLCD: 33.21 (-0.79), BMRN: 97.57 (-0.38), ALXN: 130.36 (-1.37), AMGN: 173.85 (+0.47), SPPI: 4.47 (-0.15)
Alexion to Present at Upcoming Investor Conferences
BusinessWire - Tue Sep 06, 9:00AM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences:
ALXN: 130.36 (-1.37), MS: 31.92 (+0.22)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 81.70 (-0.08), ALXN: 130.36 (-1.37), MYL: 41.91 (+0.65), AMGN: 173.85 (+0.47), ARIA: 13.41 (+0.51), RIGL: 3.48 (-0.02), REGN: 406.52 (+0.28)
After Yesterday's Decline of 1.73%, Alexion Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 2:13PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $125.69 to a high of $128.72. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $127.28 on volume of 465,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 130.36 (-1.37)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 5.08 (+0.42), PACB: 9.29 (+0.49), BMRN: 97.57 (-0.38), ALXN: 130.36 (-1.37)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 65.12 (+0.28), GERN: 2.25 (+0.20), ALXN: 130.36 (-1.37), ANIK: 47.93 (+0.34)
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
BusinessWire - Mon Aug 29, 3:33PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease (GVHD). Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract (GI-GVHD), a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation.(1,2,3)
ALXN: 130.36 (-1.37)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 81.03 (+0.13), BIIB: 312.00 (+4.95), PTLA: 23.80 (+0.32), CLVS: 35.68 (+0.85), GILD: 81.70 (-0.08), ALXN: 130.36 (-1.37), REGN: 406.52 (+0.28)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 1:30PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.06 to a high of $136.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $134.43 on volume of 524,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 130.36 (-1.37)
New Strong Sell Stocks for August 22nd
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
SYT: 87.59 (+0.44), HSNI: 38.53 (+0.41), ALXN: 130.36 (-1.37), CBT: 51.46 (+0.96), WAGE: 63.88 (-0.21)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.44%
Comtex SmarTrend(R) - Mon Aug 15, 2:19PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.83 to a high of $136.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $135.49 on volume of 630,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 130.36 (-1.37)
New Strong Sell Stocks for August 15th
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 6:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
ACHC: 49.22 (-0.98), ABAX: 51.85 (+0.37), ARCB: 18.99 (+0.19), AV: 11.76 (+0.36), ALXN: 130.36 (-1.37)
SmarTrend Watching for Potential Rebound in Shares of Alexion Pharmaceuticals After 2.29% Loss
Comtex SmarTrend(R) - Wed Sep 21, 1:49PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $128.10 to a high of $132.83. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $128.42 on volume of 419,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 130.36 (-1.37)
Watch for Alexion Pharmaceuticals to Potentially Pullback After Gaining 1.79% Yesterday
Comtex SmarTrend(R) - Wed Sep 14, 1:36PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $126.59 to a high of $130.39. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $129.52 on volume of 397,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 130.36 (-1.37)
Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare Diseases
BusinessWire - Tue Sep 13, 3:05PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of Uncommon Strength, a global campaign to raise awareness of rare diseases through the celebration of the extraordinary resilience and inner strength of those impacted by these diseases. Uncommon Strength (www.UncommonStrength.com) supports global rare disease communities, including those impacted by atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D) with educational information as well as interactive social media elements to unite the community.
ALXN: 130.36 (-1.37)
Don’t Get Caught with These Stocks this Week According to Forcerank
ESTMZ - Tue Sep 13, 8:16AM CDT
Each week Forcerank runs a variety of games covering different industries. What we have found, is that the lowest ranked companies in their respective games deliver the biggest negative price movement for that week. This week the losers include...
SKYW: 25.69 (+0.33), SPY: 215.82 (+2.40), BX: 26.35 (+0.39), SHAK: 34.35 (+0.25), TRMB: 27.40 (+0.54), AMCX: 51.42 (+0.47), ALXN: 130.36 (-1.37), VFC: 56.72 (+0.58), CTRP: 45.33 (+1.24), INTU: 110.78 (+1.81), YNDX: 21.54 (+0.84)
Everbridge to Showcase Safety Connection(TM) and Growing Partner Ecosystem at ASIS 2016
BusinessWire - Thu Sep 08, 4:26PM CDT
Everbridge, a global software company that provides critical communications and enterprise safety applications to help keep people safe and businesses running, will have a significant presence at global security technology conference, ASIS 2016 (September 12 - 15 in Orlando, Florida). The company will be in booth #1773 to highlight the latest enhancements to Safety Connection(TM), designed to help businesses quickly assess threats, locate people potentially in harm's way and automate actions and communicate with their employees when critical events occur. Everbridge will also participate in a joint speaking session with customer, Alexion Pharmaceuticals Inc., and demonstrate a variety of technical integrations and partnerships with other leading security providers throughout the show.
ALXN: 130.36 (-1.37)
Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled
Arpita Dutt - Zacks Investment Research - Wed Sep 07, 8:30AM CDT
Although it was a relatively slow week for the biotech sector, companies like CoLucid (CLCD) and Dynavax were in the news with pipeline updates.
DVAX: 11.67 (-0.33), BIIB: 312.00 (+4.95), CLCD: 33.21 (-0.79), BMRN: 97.57 (-0.38), ALXN: 130.36 (-1.37), AMGN: 173.85 (+0.47), SPPI: 4.47 (-0.15)
Alexion to Present at Upcoming Investor Conferences
BusinessWire - Tue Sep 06, 9:00AM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences:
ALXN: 130.36 (-1.37), MS: 31.92 (+0.22)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 81.70 (-0.08), ALXN: 130.36 (-1.37), MYL: 41.91 (+0.65), AMGN: 173.85 (+0.47), ARIA: 13.41 (+0.51), RIGL: 3.48 (-0.02), REGN: 406.52 (+0.28)
After Yesterday's Decline of 1.73%, Alexion Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 2:13PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $125.69 to a high of $128.72. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $127.28 on volume of 465,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 130.36 (-1.37)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 5.08 (+0.42), PACB: 9.29 (+0.49), BMRN: 97.57 (-0.38), ALXN: 130.36 (-1.37)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 65.12 (+0.28), GERN: 2.25 (+0.20), ALXN: 130.36 (-1.37), ANIK: 47.93 (+0.34)
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
BusinessWire - Mon Aug 29, 3:33PM CDT
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for the treatment of graft-versus-host disease (GVHD). Alexion is currently investigating ALXN1007 in patients with acute GVHD of the lower gastrointestinal tract (GI-GVHD), a severe and life-threatening rare autoimmune disease that can occur as a complication of stem cell or bone marrow transplantation.(1,2,3)
ALXN: 130.36 (-1.37)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 81.03 (+0.13), BIIB: 312.00 (+4.95), PTLA: 23.80 (+0.32), CLVS: 35.68 (+0.85), GILD: 81.70 (-0.08), ALXN: 130.36 (-1.37), REGN: 406.52 (+0.28)
After Yesterday's Rally of 3.12% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 1:30PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.06 to a high of $136.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $134.43 on volume of 524,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 130.36 (-1.37)
New Strong Sell Stocks for August 22nd
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
SYT: 87.59 (+0.44), HSNI: 38.53 (+0.41), ALXN: 130.36 (-1.37), CBT: 51.46 (+0.96), WAGE: 63.88 (-0.21)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.44%
Comtex SmarTrend(R) - Mon Aug 15, 2:19PM CDT
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $133.83 to a high of $136.70. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $135.49 on volume of 630,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 130.36 (-1.37)
New Strong Sell Stocks for August 15th
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 6:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
ACHC: 49.22 (-0.98), ABAX: 51.85 (+0.37), ARCB: 18.99 (+0.19), AV: 11.76 (+0.36), ALXN: 130.36 (-1.37)
(0)
(0)Scroll down for more posts ▼